Key result
Rivaroxaban plus antiplatelet therapy reduces recurrent vascular events in ACS despite increased major bleeding.
Why the study?
Does rivaroxaban added to standard antiplatelet therapy reduce recurrent vascular events in patients with acute coronary syndrome?
Does rivaroxaban added to standard antiplatelet therapy reduce recurrent vascular events in patients with acute coronary syndrome?
The addition of low-dose rivaroxaban to dual antiplatelet therapy improves secondary prevention outcomes in ACS patients, despite an increased risk of major bleeding.
Answers are grounded in this paper and cite their sources.
May warrant low-dose rivaroxaban addition in select ACS patients; leaves open net benefit optimization amid bleeding risks.
Patients with acute coronary syndrome (ACS) are typically managed with long-term dual antiplatelet therapy of acetylsalicylic acid plus a P2Y12 platelet receptor antagonist; however, although effective, the risk of another vascular event within 12 months remains at approximately 10%. Considerable efforts have been made to find improved therapeutic approaches to secondary prevention in ACS. The ATLAS ACS 2-TIMI 51 trial demonstrated that rivaroxaban (2.5 mg twice daily) significantly reduced recurrent vascular events, increased the risk of major bleeding but not the risk of fatal bleeding, and resulted in reduced rates of death from cardiovascular causes. These results formed the basis for approval in Europe of rivaroxaban (2.5 mg twice daily) in conjunction with standard antiplatelet therapy for the secondary prevention of ACS.
No takes yet. Share an insight, caveat, or question.
Alexander G. G. Turpie (2014) conducted a review in Acute coronary syndrome. Rivaroxaban vs. Standard antiplatelet therapy was evaluated on Recurrent vascular events. Rivaroxaban (2.5 mg twice daily) added to standard antiplatelet therapy significantly reduced recurrent vascular events and cardiovascular death in ACS patients, despite increased major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: